Danaher is launching an AI-powered autonomous lab for drug discovery
The lab, based at Abcam and expected to operate at scale in early 2027, aims to cut the time from idea to validated reagent by up to 8 times
Paris-based BioTech and AI company Rivercell has exited stealth mode with a €22 million ($25 million) Seed round led by HV. The investment will support Rivercell's data generation platform, expansion of its Paris lab, and launch of the AI Virtual Cell programme. Yann Fleureau, co-founder and CEO of Rivercell, emphasizes the importance of a world model of the cell as the "opportunity of the century in medicine."
The investment follows a year of active funding for European AI-focused life sciences startups, including €100.7 million across 2026. France is represented by companies such as Generare and WhiteLab Genomics, highlighting the growing trend of investment in biological data generation and computational models for pharmaceutical research.
Rivercell's proprietary platform generates high-quality single-cell data at scale, which trains its AI world model to predict cell responses to drugs and genetic changes, potentially accelerating drug discovery by reducing reliance on physical wet-lab experiments.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
